Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Investor Presentation (May 2021)
24 slides from Staar Surgical's investor presentation, May 27, 2021
Slide 1: STAAR Surgical Company Investor Presentation May 2021
STAAR Surgical Company Investor presentation May 2021 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2021 or prospects for achieving such
Slide 3: Investment Opportunity: The Future of Refractive Surgery is Lens-Based
Investment Opportunity The Future of Refractive Surgery is Lens-Based... The Time for STAAR is Now 3
Slide 4: STAAR is Targeting Two Large Markets
TAM STAAR is Targeting Two Large Markets 4 1.9 Billion Myopes Myopia Distance Vision (Nearsightedness) 1.7 Billion Presbyopes Presbyopia Near Vision (Reading Glasses) * Company estimates of viable market opportunity. 35 Million Myopes = 70 Million Lenses and 55 Million Presbyopes = 110 Million Lense
Slide 5: TAM Tailwinds Drive Future Market Growth
TAM Tailwinds Drive Future Market Growth …to dramatically increase STAAR’s Opportunity. * BHVI, adapted from Holden et al. 2016 Ophthalmology. ** Fricke, Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia. *** Company estimates. 5 Number of myopes (millions) Myopia* My
Slide 6: Refractive Market: Capture LVC Share and Grow Total Market
Refractive Market* STAAR’s Opportunity is to capture existing LVC market share and grow the total market… 6 * Market Scope, December 2019, January 2021 and Company estimates. One Eye = One Procedure. Procedures rounded to nearest 100,000 or 10,000. R.O.W = Rest of World. 4 Million Annual Global Refr
Slide 7: STAAR's Market: Global Eyeprint Countries
STAAR’s Market Global “Eyeprint” 75 Countries 7 Hybrid China S. Korea India Direct United States Canada Japan Germany Spain UK Distributor Hybrid Targets Building Out Hybrid Model in Benelux, Italy and France
Slide 8: ICL Industry-Leading Growth
ICL™ Industry-Leading Growth* 8 ICL Unit Growth vs. Industry (Y/Y) Global ICL Unit Growth Significantly Exceeded Refractive Industry in both 2019 and 2020… 1Q 2021 ICL Unit Growth Up +54% Y/Y * Global Industry procedure growth per Market Scope. Company reports and select ICL markets for fiscal years
Slide 9: ICL Technology: 87% of Net Sales Mix
ICL™ Technology x 87% of Net Sales Mix* EVO ICL™ Family of Lenses Spheric (Myopia) Toric (Myopia + Astigmatism) EVO+ (Larger Optic) Viva™ (Presbyopia) Visian ICL™ Family of Lenses Requires pre-surgical peripheral iridotomy x 9 The addition of the central port to the EVO/EVO+ sphere and toric ICL len
Slide 10: EVO ICL Technology: A Closer Look
EVO ICL™ Technology A Closer Look The EVO lens is implanted in the posterior chamber of the eye. It is positioned behind the iris and in front of the natural lens The EVO ICL is not visible to other people after implantation 10 ICL™
Slide 11: Premium and Primary Positioning: Advantages of STAAR's Proprietary Lenses
Premium and Primary Positioning EVO ICL™ Technology x x A Closer Look Advantages of STAAR’s Proprietary Lenses 11
Slide 12: 99.4% of Patients Would Elect EVO Implantable Collamer Lens Again
99.4% of Patients 12 Would Elect STAAR’s EVO Implantable Collamer® Lens Again* Over 1 Million ICLs Implanted Globally * EVO ICL Patient Registry data on file.
Slide 13: What's Going On in Active Markets Globally
What’s Going On in Active Markets Globally…
Slide 14: China: Continuing Momentum and Market Share Gains
China What’s Going On… 14 Continuing Momentum and Market Share Gains in #1 Market Globally Myopia widespread among Chinese population, and particularly teenagers* First large market to adopt a model of strategic cooperation in 2016 “Primary”, “Premium” and “High Definition” messages used to position
Slide 15: United States: What's Going On
United States What’s Going On… Increased surgeon engagement with Inaugural Surgeons Council Meeting August 2019 and Refractive Restart, Refractive Rethink and Refractive Relook programs began in 2020 to support surgeon partners, practices and patients Signed dozens of Strategic Agreements with poten
Slide 16: Europe: Germany, Spain and EVO Viva Rollout
German refractive society expanded recommended range for use of phakic refractive lenses, including EVO from -6.0D to -3.0D* in 2019 Sales & Marketing investments include increasing influencer and social media consumer focused initiatives Germany recently celebrated 5th Anniversary of conversion to
Slide 17: Impactful Consumer Marketing Driving Increasing ICL Awareness
Impactful Consumer Marketing is Driving Increasing ICL Awareness, Doctor Finder Visits and Patients to Surgeons 17 Global Consumer Marketing What’s Going On… +98% Y/Y Increase in FY 2020 Doc Finder Visits
Slide 18: STAAR's Proven Track Record of Operating and Financial Execution
STAAR’s Proven Track Record of Operating and Financial Execution…
Slide 19: Industry Leading Sales Growth
Industry Leading Sales Growth… Three-Year (2017-2020) 22% CAGR 2021 Sales Outlook for Growth Exceeding +30% 19 Net Sales $ and Growth Y/Y Source: As reported. Three-Year compound annual growth rate (CAGR) calculated from 2017-2020. *Initial sales outlook provided prior to COVID-19 on January 13, 202
Slide 20: Growth Drives Margins, EPS and Cash from Operations
Growth Drives… 20 Gross Margin GAAP EPS * 2019 Includes $0.07 GILTI tax benefit Improving Margins GAAP EPS Profitability Cash from Operations Operating Margin Cash from Operations
Slide 21: Increasing Cash on Balance Sheet
21 Increasing Cas on Balance Sheet Demonstrated Commitment to be Good Stewards of Shareholder Capital $162.3 million of Cash at April 2, 2021 21 Increasing Cash on Balance Sheet Demonstrated Commitment to be Good Stewards of Shareholder Capital $162.3 million of Cash at April 2, 2021 Approximately 9
Slide 22: 1Q Earnings Report Key Takeaways
1Q Earnings Report Key Takeaways May 5, 2021 1Q Net Sales Up 44% Y/Y to $50.8 million continued the increasing momentum from second half 2020 results 1Q ICL Unit Growth Up 54% Y/Y included China up 63%, Japan up 72%, Korea up 29%, Rest of Asia Pacific up 63%, Spain up 42%, Germany up 48%, Distributo
Slide 23: STAAR's Vision 2020-2022 Strategic Imperatives
STAAR’s Vision 2020-2022 Strategic Imperatives Position EVO Implantable Lenses as a Special and Transformational Pathway to Visual Freedom… Promote Exceptional Desirability to Win Consumer Choice and Social Media Enthusiasm Support the Transformation of the Refractive Surgery Paradigm through Clinic
Slide 24: The Time for STAAR is Now
The Future of Refractive Surgery is Lens-Based. The Time for STAAR is Now! We invite you to visit STAAR’s investor website for clinical papers, examples of global consumer marketing and much more at investors.staar.com www.staar.com www.discoverevo.com